Clinical Research

Clinical Research

LVPEI has been successfully audited by United States - Food and Drug Administration Agency (US FDA) and European Medicine Agency (EMA) for performing clinical trials.

Raja Narayanan, Director, Clinical Research
Contact: 040 68102618
Mail: narayanan@lvpei.org


Kallam Anji Reddy Campus
Manager Operations: T. Charitha
Study Coordinators: Vijaya Lakshmi , Lavanya Durga, Kalpana, Sai Sravan
Study Optometrist: Amelia Langstan, Agniv Datta, Liviza
Senior Clinical Data Analyst : E. Shobha Laxmi
Data Entry Operator: Kavya

Contact Number: 040- 68102123/2124
Contact Number (Bio statistician and Image Reading center): 040 68102170


Bhubaneswar Campus
Clinical Research Coordinators: Satyajit Parida, Bikash chandra Mohanta, Gajala
Study Optometrists: Mr.Krushna Gopal Panda, Mr. Aniruddha Banerjee , Sujoy Mukharjee

Contact Numbers(Clinical Research): 0674 2653108
Ethics Committee Coordinator: Hasibur Rahman: 0674 2653108


GMRV Campus
Clinical Research Coordinator: Ramya Sidagam, Siva Ram, Shivaji
Study Optometrist: Ram kumar, Revati, Dhanunjai, Gouthami, Vinod Kumar, Yamuna Rani

Contact Numbers(Clinical Research): 08916714079

MTC Campus
S.No Title of the Project Principal Investigator Supported By
1. XBRANE:A Phase III Doubled-Blind, Parallel Group, Multicentre study to compare the efficacy and safety of Xlucare versus Lucentis in Patients with Neo vascular Age- Related Macular Degeneration Dr Umesh Chandra Behera Syneos Health
2. LUPIN: A Prospective, Randomised, Parallel Group, Double Blind, Multicentre Study to Compare the Efficacy , Safety & Immunogenicity of Lupin's Ranibizumab with LucentisR in Patients with Neovascular Age- Related Macular Degeneration Dr Tapas Ranjan Das Lupin
3. QILU: A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration Dr Umesh Chandra Syneos Health
4. MYLAN: A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea®in Subjects with Diabetic Macular Edema Dr Umesh Chandra CLIANTHA RESEARCH

KAR CAMPUS
S.No Title of the Project Principal Investigator Supported By
1. XBRANE:A Phase III Doubled-Blind, Parallel Group, Multicentre study to compare the efficacy and safety of Xlucare versus Lucentis in Patients with Neo vascular Age- Related Macular Degeneration Dr Hitesh Agrawal SYNEOS HEALTH
2. LUPIN: A Prospective, Randomised, Parallel Group, Double Blind, Multicentre Study to Compare the Efficacy , Safety & Immunogenicity of Lupin's Ranibizumab with LucentisR in Patients with Neovascular Age- Related Macular Degeneration Dr Mudit Tyagi LUPIN PHARMA
3. JSS: A Phase IV Controlled Clinical Study to Compare the efficacy and Safety of CYCLOSPORINE (0.05%) Ophthalmic Emulsion against RESTASISR in subjects with Moderate to serve Keratoconjunctivitis Sicca Dr Sayan Basu JSS RESEARCH
4. EYLEA: Structured Post-marketing surveillance to collect the safety data of intravitreal aflibercept injection (IVTAFL) in patients of wet age-related macular degeneration during real world clinical practice. Dr Raja Narayanan BAYER
5. KITE:A Two-Year, Two-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema Dr Raja Narayanan NOVARTIS
6. PANOPTIX: An observational , Prospective , post Marketing Clinical Study of the ACRYSOF IQ PanOptix Multifocal IOL in an Indian Population Dr Jagadesh C Reddy ALCON
7. FOCUS:: Long Term effects of semaglutide on Diabetic Retinopathy in subjects with type 2 Diabetes (FOCUS) Dr Padmaja K Rani NOVONORDISK
8. MYLAN:A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea®in Subjects with Diabetic Macular Edema Dr Komal Agrawal CLIANTHA RESEARCH
9. QILU: A Randomized Phase 3, Double-masked,Parallel-group, Multicenter study to compare efficacy and safety of QL1205 Versus Lucentis in subjects with Neovascular Age Related Macular Degeneration Dr Hitesh Agrawal Syneos Health

GMRV CAMPUS
S.No Title of the Project Principal Investigator Supported By
1. XBRANE:A Phase III Doubled-Blind, Parallel Group, Multicentre study to compare the efficacy and safety of Xlucare versus Lucentis in Patients with Neo vascular Age- Related Macular Degeneration Dr Bhavik Panchal SYNEOS HEALTH
2. MYLAN: A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea®in Subjects with Diabetic Macular Edema Dr Rishikesh CLIANTHA RESEARCH
3. QILU: A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration Dr Bhavik Panchal SYNEOS HEALTH
4. IVIEW-1201-01-AIC: A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of IVIEW-1201 In The Treatment Of Acute Adenoviral Conjunctivitis Dr Merle Fernandes Excel life sciences

KVC CAMPUS
S.No Title of the Project Principal Investigator Supported By
1. Evaluation of efficacy and safety of bimatoprost 0.01% ( Careprost) preservative-free (PF) ophthalmic solution in comparison to conventional bimatoprost 0.01% (Lumigan) ophthalmic solution for glaucoma or ocular hypertension in Indian Population Dr Vivekananda Reddy SUN PHARMA